Lily D Yan1, Sarah S Matuja2, Kevin J Pain3, Margaret L McNairy1, Anthony O Etyang4, Robert N Peck1,2,5. 1. Center for Global Health and Division of General Internal Medicine (L.D.Y., M.L.M., R.N.P.), Weill Cornell Medicine, New York, NY. 2. Department of Medicine, Weill Bugando School of Medicine, Mwanza, Tanzania (S.S.M., R.N.P.). 3. Samuel J. Wood Library and C.V. Starr Biomedical Information Center (K.J.P.), Weill Cornell Medicine, New York, NY. 4. KEMRI-Wellcome Trust Research Program, Kilifi, Kenya (A.O.E.). 5. Mwanza Interventions Trial Unit, Mwanza, Tanzania (R.N.P.).
Abstract
BACKGROUND: Sub-Saharan Africa (SSA) has the highest age-adjusted burden of hypertension and cardiovascular disease (CVD). SSA also experiences many viral infections due to unique environmental and societal factors. The purpose of this narrative review is to examine evidence around how hypertension, CVD, and emerging viral infections interact in SSA. METHODS: In September 2021, we conducted a search in MEDLINE, Embase, and Scopus, limited to English language studies published since 1990, and found a total of 1169 articles. Forty-seven original studies were included, with 32 on COVID-19 and 15 on other emerging viruses. RESULTS: Seven articles, including those with the largest sample size and most robust study design, found an association between preexisting hypertension or CVD and COVID-19 severity or death. Ten smaller studies found no association, and 17 did not calculate statistics to compare groups. Two studies assessed the impact of COVID-19 on incident CVD, with one finding an increase in stroke admissions. For other emerging viruses, 3 studies did not find an association between preexisting hypertension or CVD on West Nile and Lassa fever mortality. Twelve studies examined other emerging viral infections and incident CVD, with 4 finding no association and 8 not calculating statistics. CONCLUSIONS: Growing evidence from COVID-19 suggests viruses, hypertension, and CVD interact on multiple levels in SSA, but research gaps remain especially for other emerging viral infections. SSA can and must play a leading role in the study and control of emerging viral infections, with expansion of research and public health infrastructure to address these interactions.
BACKGROUND: Sub-Saharan Africa (SSA) has the highest age-adjusted burden of hypertension and cardiovascular disease (CVD). SSA also experiences many viral infections due to unique environmental and societal factors. The purpose of this narrative review is to examine evidence around how hypertension, CVD, and emerging viral infections interact in SSA. METHODS: In September 2021, we conducted a search in MEDLINE, Embase, and Scopus, limited to English language studies published since 1990, and found a total of 1169 articles. Forty-seven original studies were included, with 32 on COVID-19 and 15 on other emerging viruses. RESULTS: Seven articles, including those with the largest sample size and most robust study design, found an association between preexisting hypertension or CVD and COVID-19 severity or death. Ten smaller studies found no association, and 17 did not calculate statistics to compare groups. Two studies assessed the impact of COVID-19 on incident CVD, with one finding an increase in stroke admissions. For other emerging viruses, 3 studies did not find an association between preexisting hypertension or CVD on West Nile and Lassa fever mortality. Twelve studies examined other emerging viral infections and incident CVD, with 4 finding no association and 8 not calculating statistics. CONCLUSIONS: Growing evidence from COVID-19 suggests viruses, hypertension, and CVD interact on multiple levels in SSA, but research gaps remain especially for other emerging viral infections. SSA can and must play a leading role in the study and control of emerging viral infections, with expansion of research and public health infrastructure to address these interactions.
Entities:
Keywords:
Africa South of the Sahara; cardiovascular diseases; hypertension; public health; virus diseases
Authors: D G Bausch; A H Demby; M Coulibaly; J Kanu; A Goba; A Bah; N Condé; H L Wurtzel; K F Cavallaro; E Lloyd; F B Baldet; S D Cissé; D Fofona; I K Savané; R T Tolno; B Mahy; K D Wagoner; T G Ksiazek; C J Peters; P E Rollin Journal: Vector Borne Zoonotic Dis Date: 2001 Impact factor: 2.133
Authors: Yohann Nédélec; Joaquín Sanz; Golshid Baharian; Zachary A Szpiech; Alain Pacis; Anne Dumaine; Jean-Christophe Grenier; Andrew Freiman; Aaron J Sams; Steven Hebert; Ariane Pagé Sabourin; Francesca Luca; Ran Blekhman; Ryan D Hernandez; Roger Pique-Regi; Jenny Tung; Vania Yotova; Luis B Barreiro Journal: Cell Date: 2016-10-20 Impact factor: 41.582
Authors: Jeremy I Schwartz; Martin Muddu; Isaac Kimera; Mary Mbuliro; Rebecca Ssennyonjo; Isaac Ssinabulya; Fred C Semitala Journal: Glob Heart Date: 2021-02-04
Authors: Yusuf Bara Jibrin; Okon Kenneth Okwong; Ibrahim Mahmood Maigari; Jacob Amos Dunga; Abubakar Muhammad Ballah; Mustapha Sabo Umar; Alkali Mohammed; Zuwaira Ibrahim Hassan Journal: Pan Afr Med J Date: 2020-10-22
Authors: Katherine Mackey; Chelsea K Ayers; Karli K Kondo; Somnath Saha; Shailesh M Advani; Sarah Young; Hunter Spencer; Max Rusek; Johanna Anderson; Stephanie Veazie; Mia Smith; Devan Kansagara Journal: Ann Intern Med Date: 2020-12-01 Impact factor: 25.391
Authors: Yannick Fogoum Fogang; Michel Noubom; Pierre-Yves Bassong; Paul Chimi Mbonda; Iliassou Njoudap Mfopou; Daniel Massi Gams; Callixte Tegueu Kuate; Joseph Kamtchum-Tatuene Journal: Pan Afr Med J Date: 2021-04-05